FDA Clearance Tracker · DEN130003
XTAG GASTROINTESTINAL PATHOGEN PANEL (GPP) XTAG DATA ANALYSIS SOFTWARE FOR GPP (TDAS)
Last checked: Nov 20, 2026Latest source record: Jan 14, 2013 (this decision)Source: openFDAMethods & limitations
Decided
Jan 14, 2013
De Novo granted
Time to decision
3 days
Received Jan 11, 2013. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Post-NSE
Device class
Class II
The decision
- FDA number
- DEN130003
- Device name
- XTAG GASTROINTESTINAL PATHOGEN PANEL (GPP) XTAG DATA ANALYSIS SOFTWARE FOR GPP (TDAS)
- Applicant
- Luminex Molecular Diagnostics, Inc.
- Applicant location
- Toronto, CA
- Received
- Jan 11, 2013
- Decided
- Jan 14, 2013
- Decision
- De Novo granted
- Submission type
- Post-NSE
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3990
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for DEN130003
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Luminex Molecular Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K242613 · Decided Oct 2, 2024 · 29 days after receipt
Device type: Respiratory Virus Panel Nucleic Acid Assay System (OCC) · Laboratory Medicine & Pathology
K231758 · Decided Mar 11, 2024 · 269 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
K193167 · Decided Dec 11, 2019 · 26 days after receipt
Device type: Respiratory Virus Panel Nucleic Acid Assay System (OCC) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.